BRISTOL-MYERS' RELOCATING SOME ANTIBIOTIC OPERATIONS TO PUERTO RICO AND ITALY from its Syracuse, N.Y. facility. The move involves filling and packaging operations and a small portion of the bulk manufacturing operation. The Syracuse facility will be phased out over the next 15-18 months and the operations consolidated into existing plants in Barceloneta, Puerto Rico and Latina, Italy. The move will affect approximately 200 employees, Bristol-Myers said. The company explained that the decision to relocate its antibiotic operations was based on the fact that the design and layout of the Syracuse facilities "makes it increasingly difficult to produce with competitive efficiency." Bristol-Myers stated that it "looked closely at redesigning and rebuilding the structures" to meet the company's needs, "but the cost was prohibitive and excess capacity already exists in" the Barceloneta and Latina plants. No decision has been made as to what will be done with the closed facilities. Bristol-Myers noted that "no regular employee will be displaced before April, 1985." In addition, the company said it has created an employee assistance program "which includes special severance pay based on age and length of service, an early retirement package, continued medical coverage, and assistance in finding new employment." Approximately 1,600 people will remain in Syracuse in the Bristol-Myers Industrial and Bristol Labs Divs.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The official separation of those impacted by the reduction-in-force and some others who are leaving the agency are not yet reflected in CDER employee gains and losses data.
A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.
In this second of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet which animal testing models have alternative options and highlights where further investment and research is needed to develop appropriate alternatives.
